サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1761077

脊椎生物製剤の世界市場

Spine Biologics

出版日
ページ情報
英文 196 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.41円
脊椎生物製剤の世界市場
出版日: 2025年07月02日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 196 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

脊椎生物製剤の世界市場は2030年までに29億米ドルに達する

2024年に22億米ドルと推定される脊椎生物製剤の世界市場は、分析期間2024-2030年にCAGR 4.4%で成長し、2030年には29億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである脊椎移植片は、CAGR 3.9%を記録し、分析期間終了時には14億米ドルに達すると予測されます。骨移植代替物セグメントの成長率は、分析期間中CAGR 5.0%と推定されます。

米国市場は5億9,320万米ドルと推定、中国はCAGR6.8％で成長予測

米国の脊椎生物製剤市場は、2024年に5億9,320万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを6.8%として、2030年までに5億9,380万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.5%と3.6%と予測されています。欧州では、ドイツがCAGR 3.0%で成長すると予測されています。

世界の脊椎生物製剤市場- 主要動向と促進要因のまとめ

なぜ脊椎生物製剤が脊椎手術と回復に変革をもたらすのか？

脊椎生物製剤は、骨再生、癒合強化、組織修復のための革新的なソリューションを提供することで、脊椎手術と回復に変革をもたらします。骨移植片、成長因子、幹細胞、合成生体材料を含むこれらの生物製剤は、脊椎固定術、椎間板置換術、脊椎変形矯正術に広く使用されています。変性椎間板症、脊柱側弯症、外傷関連損傷などの脊椎疾患の有病率の増加に伴い、癒合率を改善し、治癒時間を短縮し、合併症を最小限に抑える生物製剤に対する需要が急速に高まっています。脊椎生物製剤は、低侵襲脊椎手術（MISS）や複雑な脊椎再建術において特に有利であり、患者により良い臨床結果と迅速な回復をもたらします。

技術の進歩は脊椎生物製剤市場にどのような影響を与えていますか？

生体材料、合成骨移植片、細胞ベースの治療法における技術の進歩は、脊椎生物製剤の有効性、安全性、適用範囲を大幅に向上させています。脱灰骨マトリックス（DBM）、遺伝子組換えヒト成長因子、同種移植骨製品などの次世代生物製剤の開発は、脊椎固定や骨治癒により効果的な選択肢を提供しています。幹細胞を用いた治療法、遺伝子治療、再生医療における革新は、組織修復、神経再生、個別化された脊椎治療に新たな可能性を提供し、牽引力を増しています。さらに、複数の生物学的製剤と合成材料を統合した生物学的製剤の組み合わせやハイブリッドソリューションの出現は、脊椎外科医が利用できる治療の選択肢を広げ、脊椎生物製剤市場の成長を支えています。

脊椎生物製剤業界の成長を牽引している市場セグメンテーションは？

製品タイプには、骨移植片、骨移植片代替物、多血小板血漿（PRP）、骨形態形成タンパク質（BMP）、細胞ベースマトリックスなどがあり、骨移植片代替物は脊椎固定術に広く使用されているため、最大の市場シェアを占めています。脊椎生物製剤の用途は、脊椎固定術、椎間板置換術、外傷修復術、変形矯正術など多岐にわたるが、脊椎固定術は、固定率を高め、骨の治癒を促進する生物製剤の需要が高いため、支配的な分野となっています。最終用途分野には病院、専門クリニック、研究機関が含まれ、病院はその高度な手術能力と集学的治療チームにより市場をリードしています。地理的には、北米と欧州が再生医療と先端生物学的製剤の高い採用率に牽引されて脊椎生物製剤の最大市場となっており、アジア太平洋は医療投資の増加と脊椎疾患の有病率の増加により急成長が見込まれています。

脊椎生物製剤市場の成長促進要因は？

脊椎生物製剤市場の成長は、低侵襲脊椎手術（MISS）における生物学的製剤の需要の高まり、生体材料、合成骨移植片、再生医療における技術進歩、癒合率、骨再生、治癒時間の向上への注目の高まりなど、いくつかの要因によってもたらされます。効果的で安全、かつ個別化された生物製剤を幅広い脊椎疾患に提供する必要性が、様々な外科的・非外科的環境において脊椎生物製剤の需要を牽引しています。次世代生物学的製剤、幹細胞を用いた治療、遺伝子治療、生物学的製剤の併用における技術革新は、再生医療、合成生体材料、個別化脊椎治療の進歩と相まって、脊椎生物製剤の有効性、安全性、市場性を高め、市場の成長を支えています。外傷、椎間板変性症、脊柱側弯症治療、脊柱変形矯正における生物学的製剤の適用拡大、エビデンスに基づく診療、臨床ガイドライン、患者教育の重視の高まりは、市場関係者に新たな機会を生み出しています。さらに、多様な患者層向けに費用対効果が高く、拡張可能なハイブリッド脊椎生物製剤の開発に注力していることが、脊椎生物製剤市場の成長をさらに促進しています。

セグメント

製品（脊椎移植片,骨移植代替物,細胞ベースマトリックス）;エンドユーザー（病院,外来手術センター（ASCs）,その他のエンドユーザー）

調査対象企業の例（注目の46社）

  • AlloSource
  • Alphatec Spine, Inc.
  • DePuy Synthes
  • Exactech, Inc.
  • Globus Medical, Inc.
  • Harvest Technologies
  • Medtronic, Inc.
  • NuVasive, Inc.

AI統合

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP14981

Global Spine Biologics Market to Reach US$2.9 Billion by 2030

The global market for Spine Biologics estimated at US$2.2 Billion in the year 2024, is expected to reach US$2.9 Billion by 2030, growing at a CAGR of 4.4% over the analysis period 2024-2030. Spinal Allografts, one of the segments analyzed in the report, is expected to record a 3.9% CAGR and reach US$1.4 Billion by the end of the analysis period. Growth in the Bone Graft Substitutes segment is estimated at 5.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$593.2 Million While China is Forecast to Grow at 6.8% CAGR

The Spine Biologics market in the U.S. is estimated at US$593.2 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$593.8 Million by the year 2030 trailing a CAGR of 6.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.5% and 3.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.0% CAGR.

Global Spine Biologics Market - Key Trends and Drivers Summarized

Why Are Spine Biologics Transforming Spine Surgery and Recovery?

Spine biologics are transforming spine surgery and recovery by offering innovative solutions for bone regeneration, fusion enhancement, and tissue repair. These biologics, which include bone grafts, growth factors, stem cells, and synthetic biomaterials, are widely used in spinal fusion procedures, disc replacement, and spinal deformity correction. With the increasing prevalence of spinal disorders such as degenerative disc disease, scoliosis, and trauma-related injuries, the demand for biologics that improve fusion rates, reduce healing times, and minimize complications is growing rapidly. Spine biologics are particularly advantageous in minimally invasive spine surgery (MISS) and complex spinal reconstructions, providing better clinical outcomes and faster recovery for patients.

How Are Technological Advancements Impacting the Spine Biologics Market?

Technological advancements in biomaterials, synthetic bone grafts, and cell-based therapies are significantly enhancing the effectiveness, safety, and application scope of spine biologics. The development of next-generation biologics, such as demineralized bone matrices (DBMs), recombinant human growth factors, and allograft bone products, is providing more effective options for spinal fusion and bone healing. Innovations in stem cell-based therapies, gene therapy, and regenerative medicine are gaining traction, offering new possibilities for tissue repair, nerve regeneration, and personalized spine care. Additionally, the emergence of combination biologics and hybrid solutions, which integrate multiple biologic agents and synthetic materials, is expanding the treatment options available for spine surgeons, supporting the growth of the spine biologics market.

Which Market Segments Are Leading the Growth of the Spine Biologics Industry?

Product types include bone grafts, bone graft substitutes, platelet-rich plasma (PRP), bone morphogenetic proteins (BMPs), and cell-based matrices, with bone graft substitutes holding the largest market share due to their widespread use in spinal fusion procedures. Applications of spine biologics span spinal fusion, disc replacement, trauma repair, and deformity correction, with spinal fusion being the dominant segment due to the high demand for biologics that enhance fusion rates and promote bone healing. End-use sectors include hospitals, specialized clinics, and research institutes, with hospitals leading the market due to their advanced surgical capabilities and multidisciplinary care teams. Geographically, North America and Europe are the largest markets for spine biologics, driven by high adoption of regenerative medicine and advanced biologic products, while Asia-Pacific is expected to witness rapid growth due to rising healthcare investments and increasing prevalence of spinal disorders.

What Are the Key Drivers of Growth in the Spine Biologics Market?

The growth in the spine biologics market is driven by several factors, including rising demand for biologics in minimally invasive spine surgery (MISS), technological advancements in biomaterials, synthetic bone grafts, and regenerative medicine, and the increasing focus on enhancing fusion rates, bone regeneration, and healing times. The need to provide effective, safe, and personalized biologics for a wide range of spinal conditions is driving the demand for spine biologics across various surgical and non-surgical settings. Technological innovations in next-generation biologics, stem cell-based therapies, gene therapy, and combination biologics, coupled with advancements in regenerative medicine, synthetic biomaterials, and personalized spine care, are enhancing the efficacy, safety, and marketability of spine biologics, supporting market growth. The expansion of biologic applications in trauma, degenerative disc disease, scoliosis treatment, and spinal deformity correction, along with the growing emphasis on evidence-based practice, clinical guidelines, and patient education, is creating new opportunities for market players. Additionally, the focus on developing cost-effective, scalable, and hybrid spine biologics for diverse patient populations is further propelling the growth of the spine biologics market.

SCOPE OF STUDY:

The report analyzes the Spine Biologics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Spinal Allografts, Bone Graft Substitutes, Cell-Based Matrix); End-Use (Hospitals, Ambulatory Surgery Centers (ASCs), Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 46 Featured) -

  • AlloSource
  • Alphatec Spine, Inc.
  • DePuy Synthes
  • Exactech, Inc.
  • Globus Medical, Inc.
  • Harvest Technologies
  • Medtronic, Inc.
  • NuVasive, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Global Economic Update
    • Spine Biologics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for Biologics in Minimally Invasive Spine Surgery (MISS) Drives Spine Biologics Market Growth
    • Increasing Focus on Enhancing Fusion Rates, Bone Regeneration, and Healing Times Spurs Adoption of Spine Biologics
    • Technological Advancements in Biomaterials, Synthetic Bone Grafts, and Cell-Based Therapies Propel Market Innovation
    • Growing Emphasis on Reducing Post-Operative Complications and Repeat Surgeries Expands Addressable Market Opportunity
    • Emergence of Next-Generation Biologics, Growth Factors, and Stem Cell-Based Products Strengthens Business Case
    • Rising Adoption of Biologics in Lumbar, Cervical, and Thoracic Spine Procedures Accelerates Market Demand
    • Focus on Developing Combination Biologics and Hybrid Solutions for Enhanced Therapeutic Efficacy Drives Market Competitiveness
    • Growing Application of Spine Biologics in Trauma, Degenerative Disc Disease, and Scoliosis Treatment Fuels Market Expansion
    • Expansion of Biologic Applications in Spinal Fusion, Disc Replacement, and Spinal Deformity Correction Spurs Market Potential
    • Shift Towards Regenerative Medicine, Personalized Spine Care, and Patient-Specific Biologics Expands Market Opportunities
    • Increasing Emphasis on Patient Education, Surgical Guidelines, and Evidence-Based Practice Creates New Opportunities
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Spine Biologics Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Spine Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Spine Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Spine Biologics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Spinal Allografts by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Spinal Allografts by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Spinal Allografts by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Bone Graft Substitutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Bone Graft Substitutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Bone Graft Substitutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Cell-based Matrix by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Cell-based Matrix by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Cell-based Matrix by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers (ASCs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Ambulatory Surgery Centers (ASCs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Ambulatory Surgery Centers (ASCs) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Spine Biologics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: USA 15-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2015, 2025 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: USA 15-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: Canada 15-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2015, 2025 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: Canada 15-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2015, 2025 & 2030
  • JAPAN
    • Spine Biologics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: Japan 15-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2015, 2025 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: Japan 15-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2015, 2025 & 2030
  • CHINA
    • Spine Biologics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 41: China Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: China 15-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2015, 2025 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: China 15-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2015, 2025 & 2030
  • EUROPE
    • Spine Biologics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Spine Biologics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Spine Biologics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Europe 15-Year Perspective for Spine Biologics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Europe 15-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2015, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: Europe 15-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2015, 2025 & 2030
  • FRANCE
    • Spine Biologics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: France 15-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2015, 2025 & 2030
    • TABLE 59: France Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: France 15-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2015, 2025 & 2030
  • GERMANY
    • Spine Biologics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: Germany 15-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2015, 2025 & 2030
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Germany 15-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Italy 15-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2015, 2025 & 2030
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: Italy 15-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Spine Biologics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: UK 15-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2015, 2025 & 2030
    • TABLE 77: UK Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: UK 15-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: Spain 15-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2015, 2025 & 2030
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: Spain 15-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: Russia 15-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2015, 2025 & 2030
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Russia 15-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 15-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2015, 2025 & 2030
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 15-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Spine Biologics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Spine Biologics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Spine Biologics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 15-Year Perspective for Spine Biologics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 15-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2015, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 15-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Spine Biologics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: Australia 15-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2015, 2025 & 2030
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: Australia 15-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2015, 2025 & 2030
  • INDIA
    • Spine Biologics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 113: India Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: India 15-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2015, 2025 & 2030
    • TABLE 116: India Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: India 15-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: South Korea 15-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2015, 2025 & 2030
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: South Korea 15-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 15-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2015, 2025 & 2030
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 15-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Spine Biologics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Spine Biologics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Spine Biologics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Latin America 15-Year Perspective for Spine Biologics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Latin America 15-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2015, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Latin America 15-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Argentina 15-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2015, 2025 & 2030
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: Argentina 15-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: Brazil 15-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2015, 2025 & 2030
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Brazil 15-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Mexico 15-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2015, 2025 & 2030
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Mexico 15-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 15-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2015, 2025 & 2030
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 15-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Spine Biologics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Spine Biologics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Spine Biologics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: Middle East 15-Year Perspective for Spine Biologics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: Middle East 15-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2015, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: Middle East 15-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: Iran 15-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2015, 2025 & 2030
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: Iran 15-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: Israel 15-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2015, 2025 & 2030
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: Israel 15-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 15-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2015, 2025 & 2030
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 15-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: UAE 15-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2015, 2025 & 2030
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: UAE 15-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 15-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2015, 2025 & 2030
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 15-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2015, 2025 & 2030
  • AFRICA
    • Spine Biologics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: Africa 15-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2015, 2025 & 2030
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 208: Africa 15-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION